Susan E Appt1, Haiying Chen, Thomas B Clarkson, Jay R Kaplan. 1. Wake Forest Primate Center and Department of Pathology/Comparative Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27157-1040, USA. sappt@wakehealth.edu
Abstract
OBJECTIVE: The aim of this study was to determine if premenopausal ovarian reserve is associated with susceptibility for atherosclerosis. METHODS: Female cynomolgus macaques (n = 66, women's equivalent age = 45 y) consumed an atherogenic diet for ∼5 months before the measurement of a marker of ovarian reserve (antimüllerian hormone [AMH]), plasma lipids, follicular phase estradiol, and body weight (BW). Monkeys were then ovariectomized (OVX; n = 17), remained premenopausal (n = 20), or were induced to have reduced ovarian reserve (ROR, n = 29). After 26 additional months consuming the diet, atherosclerosis measurements and risk variables were reassessed. RESULTS: No differences in baseline AMH, plasma lipids, BW, and estradiol or postdiet lipids and BW were observed among the groups subsequently assigned to the OVX, premenopausal control, or reduced ovarian reserve conditions. Postdiet measurements of atherosclerosis extent did not differ among the groups. However, analysis of plaque size by tertile of baseline AMH revealed that plaques were largest in monkeys that began the experiment with the lowest baseline AMH, followed by those in the middle and high tertiles (plaque extent: low AMH, 0.76 ± 0.12 mm; mid AMH, 0.46 ± 0.1 mm; high AMH, 0.34 ± 0.08 mm; P = 0.02). Baseline AMH and plaque size were also correlated negatively (r = -0.31, P = 0.01). Plasma lipids were also correlated significantly with plaque extent (all P < 0.01) but not with AMH. CONCLUSIONS: We report for the first time an inverse relationship between a marker of ovarian reserve (AMH) and subsequent atherosclerosis risk.
OBJECTIVE: The aim of this study was to determine if premenopausal ovarian reserve is associated with susceptibility for atherosclerosis. METHODS: Female cynomolgus macaques (n = 66, women's equivalent age = 45 y) consumed an atherogenic diet for ∼5 months before the measurement of a marker of ovarian reserve (antimüllerian hormone [AMH]), plasma lipids, follicular phase estradiol, and body weight (BW). Monkeys were then ovariectomized (OVX; n = 17), remained premenopausal (n = 20), or were induced to have reduced ovarian reserve (ROR, n = 29). After 26 additional months consuming the diet, atherosclerosis measurements and risk variables were reassessed. RESULTS: No differences in baseline AMH, plasma lipids, BW, and estradiol or postdiet lipids and BW were observed among the groups subsequently assigned to the OVX, premenopausal control, or reduced ovarian reserve conditions. Postdiet measurements of atherosclerosis extent did not differ among the groups. However, analysis of plaque size by tertile of baseline AMH revealed that plaques were largest in monkeys that began the experiment with the lowest baseline AMH, followed by those in the middle and high tertiles (plaque extent: low AMH, 0.76 ± 0.12 mm; mid AMH, 0.46 ± 0.1 mm; high AMH, 0.34 ± 0.08 mm; P = 0.02). Baseline AMH and plaque size were also correlated negatively (r = -0.31, P = 0.01). Plasma lipids were also correlated significantly with plaque extent (all P < 0.01) but not with AMH. CONCLUSIONS: We report for the first time an inverse relationship between a marker of ovarian reserve (AMH) and subsequent atherosclerosis risk.
Authors: Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner Journal: Circulation Date: 2012-01-03 Impact factor: 29.690
Authors: S L Broer; M J C Eijkemans; G J Scheffer; I A J van Rooij; A de Vet; A P N Themmen; J S E Laven; F H de Jong; E R Te Velde; B C Fauser; F J M Broekmans Journal: J Clin Endocrinol Metab Date: 2011-05-25 Impact factor: 5.958
Authors: J R Kaplan; H Chen; S E Appt; C J Lees; A A Franke; S L Berga; M E Wilson; S B Manuck; T B Clarkson Journal: Hum Reprod Date: 2010-10-17 Impact factor: 6.918
Authors: Sara E Looby; Kathleen V Fitch; Suman Srinivasa; Janet Lo; Danielle Rafferty; Amanda Martin; Judith C Currier; Steven Grinspoon; Markella V Zanni Journal: AIDS Date: 2016-01-28 Impact factor: 4.177
Authors: Alex J Polotsky; Amanda A Allshouse; Sybil L Crawford; Sioban D Harlow; Naila Khalil; Rasa Kazlauskaite; Nanette Santoro; Richard S Legro Journal: J Clin Endocrinol Metab Date: 2014-02-11 Impact factor: 5.958
Authors: Julie S Rios; Eleni A Greenwood; Mary Ellen G Pavone; Marcelle I Cedars; Richard S Legro; Michael P Diamond; Nanette Santoro; Fangbai Sun; Randal D Robinson; Gregory Christman; Heping Zhang; Heather G Huddleston Journal: J Clin Endocrinol Metab Date: 2020-01-01 Impact factor: 5.958
Authors: Yih Harng Chong; Nicola A Dennis; Martin J Connolly; Ruth Teh; Gregory T Jones; Andre M van Rij; Stephanie Farrand; A John Campbell; Ian S McLennan; Ian S Mlennan Journal: PLoS One Date: 2013-08-05 Impact factor: 3.240
Authors: Emma L Anderson; Abigail Fraser; William McNally; Naveed Sattar; Hany Lashen; Richard Fleming; Scott M Nelson; Debbie A Lawlor Journal: PLoS One Date: 2013-05-31 Impact factor: 3.240